Related Experiment Videos
Case report: cyclosporin A-induced neurotoxicity
L Monteiro1, J Almeida-Pinto, N Rocha
1Department of Neurology, Hospital Geral de Santo António, Oporto, Portugal.
The British Journal of Radiology
|March 1, 1993
Summary
Cyclosporin A (CsA) can cause acute encephalopathy, a brain condition, in transplant patients. This case highlights CsA neurotoxicity in a young patient with uveitis, indicating potential risks with wider CsA use.
Area of Science:
- Neuroscience
- Toxicology
- Ophthalmology
Background:
- Cyclosporin A (CsA) is an immunosuppressant commonly used in organ transplantation.
- Acute encephalopathy is a known, albeit rare, neurotoxic side effect of CsA therapy.
- Idiopathic uveitis is an inflammatory eye condition that can be treated with CsA.
Observation:
- A 16-year-old female patient with idiopathic uveitis was treated with CsA and methylprednisolone.
- Two weeks post-treatment, the patient developed symptoms of acute encephalopathy.
- Neuroimaging revealed occipital lobe cortical and white matter abnormalities.
Findings:
- The observed occipital changes on MRI resolved within two months of treatment cessation.
- This case demonstrates a clear association between CsA administration and reversible neurotoxicity.
- The patient's presentation underscores the potential for CsA-induced encephalopathy outside of the typical transplant population.
Implications:
- As indications for CsA expand, clinicians should be vigilant for neurotoxic effects, even in non-transplant settings.
- Early recognition and management of CsA neurotoxicity are crucial for favorable outcomes.
- Further research into the mechanisms of CsA neurotoxicity may inform safer prescribing practices.